Filtered By:
Condition: Stroke
Management: Medicaid
This page shows you your search results in order of date. This is page number 19.
Order by Relevance | Date
Total 372 results found since Jan 2013.
Recombinant Tissue Plasminogen Activator Stroke Therapy
The results of recently completed clinical trials of acute ischemic stroke that report a clear and unequivocal benefit of stent-retriever devices used with intravenous recombinant tissue plasminogen activator (rtPA) vs rtPA alone are the second revolutionary therapeutic breakthrough in acute stroke care in the last 50 years. This breakthrough makes the case for a new standard of care for the treatment of acute ischemic stroke. When we look back at the controversy surrounding interventional acute stroke therapies after multiple trials of interventional treatment, most notably International Management of Stroke III (IMS III)...
Source: JAMA Neurology - January 25, 2016 Category: Neurology Source Type: research
Antithrombotic use and bleeding risk in patients with atrial fibrillation: findings from a multipayer analysis.
CONCLUSION: Levels of thromboprophylaxis for high-risk AF patients in real-world data differ significantly from current medical guidelines for stroke prevention.
PMID: 26690040 [PubMed - as supplied by publisher]
Source: Journal of Comparative Effectiveness Research - December 23, 2015 Category: Journals (General) Tags: J Comp Eff Res Source Type: research
MPPR Rollback and Mammography Protections in Consolidated Appropriations Act: A Victory for Patients and Providers
The American College of Radiology (ACR) applauds Congress for including access to imaging care protections for the most sick and injured of Medicare beneficiaries and women seeking mammograms in the Consolidated Appropriations Act. The legislation was passed by Congress and signed into law by the President today (Dec. 18).
“The ACR, its member physicians, patients and others have worked with Congress to improve and safeguard patient access to vital imaging care through the protections in this bill. The access to care that these steps will allow can literally mean the difference between life and death for many Americ...
Source: American College of Radiology - December 18, 2015 Category: Radiology Source Type: news
Study: Boston Scientific’s Watchman cheaper than drugs in reducing afib stroke risk
A study comparing the stroke risk for atrial fibrillation patients treated with Boston Scientific‘s (NYSE:BSX) Watchman device with the anticoagulant drug warfarin and non-warfarin oral anticoagulants found Watchman to be more cost-effective than its counterparts.
Watchman is a catheter-delivered cardiac implant designed to close off the left atrial appendage, to prevent blood clots from forming there that could later cause a stroke.
The study, published online in the Journal of the American College of Cardiology, showed that the Watchman device was cost-effective at 7 years at a cost of $42,994 per quality-adjust...
Source: Mass Device - December 15, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: Wall Street Beat Cardiovascular Cardiac Implants Clinical Trials Boston Scientific Reimbursement Source Type: news
Time to Cost-Effectiveness Following Stroke Reduction Strategies in AF Warfarin Versus NOACs Versus LAA Closure
ConclusionsBoth NOACs and LAAC with the Watchman device were cost-effective relative to warfarin, but LAAC was also found to be cost-effective and to offer better value relative to NOACs. The results of this analysis should be considered when formulating policy and practice guidelines for stroke prevention in AF.
Source: Journal of the American College of Cardiology - December 14, 2015 Category: Cardiology Source Type: research
MassDevice.com +3 | The top 3 medtech stories for November 24, 2015
Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
3. Ocular Therapeutix launches another pivotal for Dextenza eye drug-device combo
Ocular Therapeutix said today that it launched another pivotal trial for its Dextenza drug-device combination, its 2nd study of the treatment for an allergic conjunctivitis indication.
Bedford, Mass.-based Ocular Th...
Source: Mass Device - November 24, 2015 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 3 Source Type: news
Report: Medicare proposal would broaden coverage for Boston Scientific’s Watchman
The Centers for Medicare & Medicaid Services are reportedly considering broadening the coverage for Boston Scientific‘s (NYSE:BSX) Watchman anti-stroke device, according to an unidentified official with the federal health insurer.
Leerink Partners analyst Danielle Antalffy, citing a Bloomberg report, wrote today that the CMS official “clarified that CMS is proposing to pay for Watchman for a subset of the patients who currently would be eligible for the device under the FDA-approved label,” or patients at high risk for stroke and bleeding and/or contraindicated to long-term warfarin use.
“Whi...
Source: Mass Device - November 24, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: Cardiac Implants Cardiovascular Wall Street Beat Boston Scientific Centers for Medicare and Medicaid Services (CMS) Reimbursement Source Type: news
Analysts: Worst case unlikely in Medicare call on Boston Scientific’s Watchman anti-stroke device
The worst-case Medicare reimbursement scenario for Boston Scientific‘s (NYSE:BSX) Watchman anti-stroke device is unlikely to play out, according to a pair of analysts.
Boston Scientific shares took a hit earlier this month after the Centers for Medicare & Medicaid Services proposed to limit coverage for the Watchman device, a transcatheter implant designed to seal off the left atrial appendage to prevent the formation of blood clots that could cause stroke. The FDA approved Watchman in March.
The federal health insurer proposed to limit coverage for Watchman to patients in approved clinical trials who can&#...
Source: Mass Device - November 23, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: Cardiac Implants Wall Street Beat Boston Scientific Centers for Medicare and Medicaid Services (CMS) Reimbursement Stroke Source Type: news
Diagnostic Imaging Services Access Protection Act Helps Preserve Care for Most Vulnerable Patients
The American College of Radiology (ACR) strongly supports the Diagnostic Imaging Services Access Protection Act (S. 1020), recently introduced by Senators David Vitter (R-LA) and Ben Cardin (D-MD). This legislation would prospectively repeal the existing 25 percent Multiple Procedure Payment Reduction (MPPR) applied to Medicare reimbursement for interpretation of advanced diagnostic imaging scans performed on the same patient, in the same session, on the same day.
The Secretary of Health and Human Services (HHS) continues to ignore a mandate in the Protecting Access to Medicare Act (PAMA) of 2014 (Public Law 113-93) to r...
Source: American College of Radiology - November 18, 2015 Category: Radiology Source Type: news
MassDevice.com +3 | The top 3 medtech stories for November 12, 2015
Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
3. SurgiQuest files for $75m IPO
SurgiQuest this week registered for an initial public offering estimated at $75 million.
Milford, Conn.-based SurgiQuest makes the AirSeal device for use in minimally invasive abdominal surgeries. AirSeal is designed to insufflate the rectum and provide continuous...
Source: Mass Device - November 12, 2015 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 3 Source Type: news
Boston Scientific dips on Medicare reimbursement hit for Watchman anti-stroke device
Boston Scientific (NYSE:BSX) shares took a hit yesterday after a Centers for Medicare & Medicaid Services proposal that would limit coverage for the Watchman anti-stroke device. Investors also likely reacted to a pair of Class II recalls from the FDA, sending BSX shares down -4.2% to $18.01 apiece yesterday.
Watchman, a transcatheter implant designed to seal off the left atrial appendage to prevent the formation of blood clots that could cause stroke, was approved by the FDA in March and asked for a CMS coverage decision in May. The federal health insurer proposed to limit coverage for Watchman to patients in approv...
Source: Mass Device - November 12, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: Cardiac Implants Cardiovascular Recalls Boston Scientific Cardiac Rhythm Management Stroke Source Type: news
The Study of Cardiovascular Health Outcomes in the Era of Claims Data: The Cardiovascular Health Study.
CONCLUSIONS: -The use of diagnostic codes from claims data as clinical events, especially when restricted to primary diagnoses, leads to an underestimation of event rates. Additionally, claims-based events data represent a composite endpoint that includes the outcome of interest and selected (misclassified) non-event hospitalizations.
PMID: 26538580 [PubMed - as supplied by publisher]
Source: Circulation - November 4, 2015 Category: Cardiology Authors: Psaty BM, Delaney JA, Arnold AM, Curtis LH, Fitzpatrick AL, Heckbert SR, McKnight B, Ives D, Gottdiener JS, Kuller LH, Longstreth WT Tags: Circulation Source Type: research
Abstract PR04: Functional mobility disparities in older African American women with cancer in a multisite lay navigation program in the Deep South
Conclusions: AA oncogeriatric females have a greater number of high risk diseases and functional mobility limitations that affect their health, compared to Caucasians. By identifying functional mobility limitations early, proactive interventions can be implemented, monitored, and adjusted to modify or resolve mobility problems that can lead to disability and health disparities in oncogeriatric females. LNs can effectively use the DT to identify functional mobility problems and empower female oncogeriatrics to resolve them; improving health and decreasing health disparities. Data will be used to continue expanding the knowl...
Source: Cancer Epidemiology Biomarkers and Prevention - September 30, 2015 Category: Cancer & Oncology Authors: Taylor, R., Acemgil, A., Meneses, K., Rocque, G., Pisu, M., Wang, X., Demark-Wahnefried, W., Partridge, E. Tags: Community-Based Interventions: Oral Presentations - Proffered Abstracts Source Type: research
MassDevice.com +3 | The top 3 medtech stories for September 17, 2015
Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
3. Battelle unveils new WayFinder hospital dashboard
Battelle said today it launched its WayFinder QI Dashboard advanced analytics tool designed to track and analyze internal data and metrics.
The Wayfinder uses statistical models to analyze pools of patient data data from hospitals and health sy...
Source: Mass Device - September 17, 2015 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 3 Source Type: news
Stroke patients fare better with private insurance than with Medicaid
Stroke victims who use Medicaid or are uninsured were more likely to die, stay hospitalized longer and have worse medical outcomes than patients with private insurance, a study has found.
Source: ScienceDaily Headlines - September 11, 2015 Category: Science Source Type: news
